Therefore, medical guidelines suggest reducing the dosage or discontinuing ACE inhibitors or ARBs in individuals with stage 5 CKD (eGFR <15 mL/min per 1.73 m2) if there is symptomatic hypotension or uncontrolled hyperkalemia [12]. This evidence concerns the gene ACE and chronic kidney disease.